(Total Views: 736)
Posted On: 11/20/2020 7:25:12 PM
Post# of 154089
Interim Data Analysis
How is it that companies are allowed access to Interim Analysis data, but Cytodyn is not. Weren't Phizer, BNTX and MRNA also allowed such access?
Humanigen (HGEN) has announced positive interim Phase 3 data of lenzilumab in patients hospitalized with COVID-19. Shares are now popping 13% in Friday’s trading.
HGEN revealed that lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37% more recoveries observed in the lenzilumab arm of the randomized, placebo-controlled, double-blinded study versus current standard of care (SOC).
How is it that companies are allowed access to Interim Analysis data, but Cytodyn is not. Weren't Phizer, BNTX and MRNA also allowed such access?
Humanigen (HGEN) has announced positive interim Phase 3 data of lenzilumab in patients hospitalized with COVID-19. Shares are now popping 13% in Friday’s trading.
HGEN revealed that lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37% more recoveries observed in the lenzilumab arm of the randomized, placebo-controlled, double-blinded study versus current standard of care (SOC).
(1)
(0)
